Top-News

VolitionRX Aktie News

Aktie
WKN:  A12B6K ISIN:  US9286611077 US-Symbol:  VNRX Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
0,3186 $
+0,0072 $
+2,31%
0,27363 € 19:23:08 Uhr
Depot/Watchlist
Marktkapitalisierung *
30,66 Mio. €
Streubesitz
62,49%
KGV
-1,94
Index-Zuordnung
-

VolitionRX News

04.12.25 - PR Newswire
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-​World Evaluation of Early Detection of Sepsis PR Newswire
25.11.25 - PR Newswire
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use PR Newswire
13.11.25 - PR Newswire
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update PR Newswire
10.11.25 - PR Newswire
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update PR Newswire
17.10.25 - PR Newswire
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-​Assisted Crisis Response Dogs PR Newswire
10.10.25 - PR Newswire
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants PR Newswire
09.10.25 - PR Newswire
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants PR Newswire
02.10.25 - PR Newswire
Volition Sponsors Upcoming GenomeWeb Webinar
Volition Sponsors Upcoming GenomeWeb Webinar PR Newswire
29.09.25 - PR Newswire
Volition Signs Co-Marketing and Services Agreement with Hologic
Volition Signs Co-​Marketing and Services Agreement with Hologic PR Newswire
09.09.25 - PR Newswire
Volition Signs First Human Out Licensing Deal
Volition Signs First Human Out Licensing Deal PR Newswire
14.08.25 - PR Newswire
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update PR Newswire
08.08.25 - PR Newswire
VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update PR Newswire
04.08.25 - PR Newswire
VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering
VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering PR Newswire
16.07.25 - PR Newswire
Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation
Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation PR Newswire
08.07.25 - PR Newswire
Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes
Volition Announces Groundbreaking Lateral Flow Test for Point-​of-Care Quantification of Nucleosomes PR Newswire
12.06.25 - PR Newswire
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure PR Newswire
04.06.25 - PR Newswire
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties PR Newswire
19.05.25 - PR Newswire
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats PR Newswire
15.05.25 - PR Newswire
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update PR Newswire
12.05.25 - PR Newswire
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »